AZD 0486
Alternative Names: AZD-0486; CD19 x CD3 T-BsAb - TeneoBio; TNB-486Latest Information Update: 29 Jan 2024
At a glance
- Originator TeneoTwo
- Developer TeneoBio; TeneoTwo
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Precursor B-cell lymphoblastic leukaemia-lymphoma
- Phase I Non-Hodgkin's lymphoma
Most Recent Events
- 29 Jan 2024 Phase-I development is still ongoing in USA (NCT04594642)
- 29 Dec 2023 Phase-I/II clinical trials in Precursor B-cell lymphoblastic leukaemia-lymphoma (Second-line therapy or greater, In adolescents, In adults, In children, In the elderly) in USA (IV) (NCT06137118)
- 09 Dec 2023 Preliminary adverse events and efficacy data from a phase I trial in Non-Hodgkin's lymphoma presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)